The nearly $4 billion iShares Nasdaq Biotechnology ETF (IBB), the largest biotechnology ETF by assets, will welcome some new stocks to its lineup on Dec. 23 when the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI) becomes effective.
The following 21 securities will be added to the Index: AcelRx Pharmaceuticals, Inc. (ACRX), Agios Pharmaceuticals, Inc. (AGIO), BioCryst Pharmaceuticals, Inc. (BCRX), bluebird bio, Inc. (BLUE), ChemoCentryx, Inc. (CCXI), Cempra, Inc. (CEMP), Chimerix, Inc. (CMRX), Epizyme, Inc. (EPZM), Esperion Therapeutics, Inc. (ESPR), Horizon Pharma, Inc. (HZNP), Cellular Dynamics International, Inc. (ICEL), Insys Therapeutics, Inc. (INSY), KYTHERA Biopharmaceuticals, Inc. (KYTH), OncoMed Pharmaceuticals, Inc. (OMED), Onconova Therapeutics, Inc. (ONTX), Prothena Corporation plc (PRTA), PTC Therapeutics, Inc. (PTCT), Portola Pharmaceuticals, Inc. (PTLA), Regulus Therapeutics Inc. (RGLS), Sagent Pharmaceuticals, Inc. (SGNT) and Verastem, Inc. (VSTM), according to a statement issued by NASDAQ OMX Global Indexes.
IBB will say good-bye to , the following 16 securities: ArQule, Inc. (ARQL), AVEO Pharmaceuticals, Inc. (AVEO), Cytori Therapeutics, Inc. (CYTX), Enzon Pharmaceuticals, Inc. (ENZN), Amicus Therapeutics, Inc. (FOLD), Furiex Pharmaceuticals, Inc. (FURX), GTx, Inc. (GTXI), Hyperion Therapeutics, Inc. (HPTX), Oncothyreon Inc. (ONTY), Pain Therapeutics, Inc. (PTIE), QLT Inc. (QLTI), SIGA Technologies, Inc. (SIGA), Santarus, Inc. (SNTS), Targacept, Inc. (TRGT), Vical Incorporated (VICL) and ViroPharma Incorporated (VPHM).
IBB allocates roughly 34% of its weight to biotech’s “Big Four” – Biogen (BIIB), Gilead (GILD), Celgene (CELG) and Amgen (AMGN). IBB is up 57.1% this year and ranks among 2013’s 10-best non-leveraged ETFs. The ETF was also on the 2011 and 2012 10 best lists. [Health Care ETFs Prescribe New Highs]
It's a product company today, not a biotech startup, with THE ONLY CURE for SMALLPOX & several other poxes, awarded a USG $2.8 Billion contract for THE CURE, WHO Nations anxious to buy THE ONLY CURE, promising work on
Dengue,and $100M+ in cash!
Buy a few or regret you did not, esp during the bargain tax selling season.
The roadblocks too will pass!
They get rid of the losers. Like being fired. Not going to be added to a a different index better or worse with a track record like siga. These index funds look for a positive return. Not based on dreams. What a Mo ron!